This is a good start, Sanofi are global behemoths clearly liking what they see and want to explore a commercial deal.
The option is for a consumer facing application, unlikely to be used in a telehealth setting.
Another company with a breakthrough platform technology I’m invested in is also taking a similar route, negotiating their technology for a single vertical and geography. It's a way of keeping the big multinationals honest and transparent.
Giving global rights to a single company for ‘x’ amount can stall a rollout. A technology like ResApp’s needs multiple commercial partners across different verticals to fast track to market.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Grants Option to Consumer Health Division of Sanofi
Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-86
-
- There are more pages in this discussion • 179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online